Physician profile
Maher Mourad
NPI 1730104076
$2,859.60
in general payments reported to CMS, 2019-2025
26 companies · $281 in 2025
The $281 reported for 2025 was more than what 82% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $488 · 2021: $330 · 2022: $125 · 2023: $498 · 2024: $789 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540 · Education: $26.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,540.11 |
| Education | $26.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $752.13 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $308.64 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.20 | 2020-2025 | Trulance, Xifaxan |
| Sanofi-Aventis U.S. LLC | $187.30 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.01 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $150.20 | 2019-2025 | Eliquis |
| Pfizer INC. | $139.61 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $125.00 | 2024 | |
| Ironwood Pharmaceuticals, INC | $97.45 | 2019 | |
| Allergan, INC. | $71.85 | 2020 | |
| Phathom Pharmaceuticals, INC. | $68.77 | 2024 | Voquezna |
| Dexcom, INC. | $60.10 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $59.21 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $51.20 | 2025 | |
| Lilly USA, LLC | $50.55 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.59 | 2020-2021 | |
| Boston Scientific Corporation | $33.84 | 2019 | |
| Corcept Therapeutics | $29.44 | 2025 | Korlym |
| Amgen INC. | $29.11 | 2020-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $26.74 | 2020 | |
| Mylan Specialty L.P. | $20.53 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.71 | 2019 | |
| Halozyme INC | $18.06 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.79 | 2025 | |
| Hikma Pharmaceuticals USA | $14.07 | 2019 | |
| Amarin Pharma, INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Mourad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.